Stock Analysis

Minerals 260 is an ASX-listed gold developer whose core asset is the Bullabulling Gold Project, located in the Goldfields region of Western Australia — one of the world's most prolific and well-understood goldMiningjurisdictions. The project benefits from proximity to established mining infrastructure, processing expertise …

Macquarie Group is a global financial services provider headquartered in Australia, operating across asset management, banking, advisory and markets-facing businesses. Its Macquarie Asset Management division is one of the world's largest infrastructure investors, managingCapitalon behalf of institutional clients across sectors including transport, energy, utilities …

Qantas Airways is Australia's flagship carrier and one of the world's oldest continuously operating airlines, running a multi-brand portfolio that spans full-service international and domestic operations under the QantasBrandalongside the low-cost Jetstar Group, which operates across Australia, New Zealand, Asia and Japan. The group's …

Vitrafy Life Sciences is a life sciences company developing cryopreservation technology aimed at improving how biological materials, including blood and blood-related products, are preserved for storage, transport and later use. Cryopreservation is a critical enabling technology across healthcare, from blood banking and transfusion medicine …

WIA Gold is an ASX-listed gold explorer and developer focused on advancing the Kokoseb Gold Project in Namibia, one of the more closely watched greenfield gold discoveries on the exchange in recent years. The company's strategy has centred on aggressive drill-out programs designed to …

Waratah Minerals is an ASX-listed exploration company focused on its Spur Gold and Copper Project in New South Wales, an asset that combines both precious and base metal potential in a single mineralised system. Gold-copper porphyry and related systems of this type are highly …

PYC Therapeutics Ltd is a clinical-stage biotechnology company focused on developing RNA-based genetic medicines designed to treat serious genetic diseases at their molecular source. The company's proprietary Precision RNA technology platform underpins its drug-development approach, aiming to deliver targeted therapies that address the underlying …